Bristol Myers Squibb Company
- Karuna Therapeutics soared 47.4% to $317.22 after Bristol Myers agreed to pay $330 per share, or $14 billion, to acquire the maker of the schizophrenia drug KarXT.
The U.S. Food and Drug Administration has accepted KarXT for a review.
Bristol-Myers declined 1.7% to $50.36.
Dec 22, 2023
If you want to see the full data, please log in to your account. Logging in gives you complete access to all available information, features, and detailed insights that are not visible to guest users.